514 related articles for article (PubMed ID: 33154194)
21. An eleven metabolic gene signature-based prognostic model for clear cell renal cell carcinoma.
Wu Y; Wei X; Feng H; Hu B; Liu B; Luan Y; Ruan Y; Liu X; Liu Z; Wang S; Liu J; Wang T
Aging (Albany NY); 2020 Nov; 12(22):23165-23186. PubMed ID: 33221754
[TBL] [Abstract][Full Text] [Related]
22. DAB2IP Plays Important Clinical Significance and Correlates With Immune Infiltration in Renal Cell Carcinoma.
Cao H; Zhang J; Wang W
Technol Cancer Res Treat; 2020; 19():1533033820936682. PubMed ID: 32583730
[TBL] [Abstract][Full Text] [Related]
23. In silico DNA methylation analysis identifies potential prognostic biomarkers in type 2 papillary renal cell carcinoma.
Yang M; Hlady RA; Zhou D; Ho TH; Robertson KD
Cancer Med; 2019 Sep; 8(12):5760-5768. PubMed ID: 31361072
[TBL] [Abstract][Full Text] [Related]
24. Identification of molecular subtypes based on chromatin regulator and tumor microenvironment infiltration characterization in papillary renal cell carcinoma.
Tang Q; Pan D; Xu C; Chen L
J Cancer Res Clin Oncol; 2023 Jan; 149(1):231-245. PubMed ID: 36404389
[TBL] [Abstract][Full Text] [Related]
25. The underlying molecular mechanism and potential drugs for treatment in papillary renal cell carcinoma: A study based on TCGA and Cmap datasets.
Pang JS; Li ZK; Lin P; Wang XD; Chen G; Yan HB; Li SH
Oncol Rep; 2019 Apr; 41(4):2089-2102. PubMed ID: 30816528
[TBL] [Abstract][Full Text] [Related]
26. Exosome-related lncRNA score: A value-based individual treatment strategy for predicting the response to immunotherapy in clear cell renal cell carcinoma.
Yang Z; Zhang X; Zhan N; Lin L; Zhang J; Peng L; Qiu T; Luo Y; Liu C; Pan C; Hu J; Ye Y; Jiang Z; Liu X; Sun M; Zhang Y
Cancer Med; 2024 Jun; 13(11):e7308. PubMed ID: 38808948
[TBL] [Abstract][Full Text] [Related]
27. Integrative analysis of DNA methylation and gene expression in papillary renal cell carcinoma.
Singh NP; Vinod PK
Mol Genet Genomics; 2020 May; 295(3):807-824. PubMed ID: 32185457
[TBL] [Abstract][Full Text] [Related]
28. TPX2 as a prognostic indicator and potential therapeutic target in clear cell renal cell carcinoma.
Glaser ZA; Love HD; Guo S; Gellert L; Chang SS; Herrell SD; Barocas DA; Penson DF; Cookson MS; Clark PE
Urol Oncol; 2017 May; 35(5):286-293. PubMed ID: 28108243
[TBL] [Abstract][Full Text] [Related]
29. Genome-wide mutation profiling and related risk signature for prognosis of papillary renal cell carcinoma.
Zhang C; Zheng Y; Li X; Hu X; Qi F; Luo J
Ann Transl Med; 2019 Sep; 7(18):427. PubMed ID: 31700863
[TBL] [Abstract][Full Text] [Related]
30. PTP4A3 Is a Prognostic Biomarker Correlated With Immune Infiltrates in Papillary Renal Cell Carcinoma.
Song Q; Zheng Y; Wu J; Wang S; Meng L; Yao Q; Li Z; Lian S
Front Immunol; 2021; 12():717688. PubMed ID: 34630392
[TBL] [Abstract][Full Text] [Related]
31. Construction of a prognostic value model in papillary renal cell carcinoma by immune-related genes.
Wang L; Gu W; Ni H
Medicine (Baltimore); 2021 Mar; 100(12):e24903. PubMed ID: 33761648
[TBL] [Abstract][Full Text] [Related]
32. Comprehensive analysis of differentially expressed profiles and reconstruction of a competing endogenous RNA network in papillary renal cell carcinoma.
Luo Q; Cui M; Deng Q; Liu J
Mol Med Rep; 2019 Jun; 19(6):4685-4696. PubMed ID: 30957192
[TBL] [Abstract][Full Text] [Related]
33. Papillary Renal Cell Carcinoma (PRCC): An Update.
Akhtar M; Al-Bozom IA; Al Hussain T
Adv Anat Pathol; 2019 Mar; 26(2):124-132. PubMed ID: 30507616
[TBL] [Abstract][Full Text] [Related]
34. Comprehensive insights on pivotal prognostic signature involved in clear cell renal cell carcinoma microenvironment using the ESTIMATE algorithm.
Luo J; Xie Y; Zheng Y; Wang C; Qi F; Hu J; Xu Y
Cancer Med; 2020 Jun; 9(12):4310-4323. PubMed ID: 32311223
[TBL] [Abstract][Full Text] [Related]
35. Prognostic Value of a Long Non-coding RNA Signature in Localized Clear Cell Renal Cell Carcinoma.
Qu L; Wang ZL; Chen Q; Li YM; He HW; Hsieh JJ; Xue S; Wu ZJ; Liu B; Tang H; Xu XF; Xu F; Wang J; Bao Y; Wang AB; Wang D; Yi XM; Zhou ZK; Shi CJ; Zhong K; Sheng ZC; Zhou YL; Jiang J; Chu XY; He J; Ge JP; Zhang ZY; Zhou WQ; Chen C; Yang JH; Sun YH; Wang LH
Eur Urol; 2018 Dec; 74(6):756-763. PubMed ID: 30143382
[TBL] [Abstract][Full Text] [Related]
36. Influence of gene expression on survival of clear cell renal cell carcinoma.
Berglund A; Amankwah EK; Kim YC; Spiess PE; Sexton WJ; Manley B; Park HY; Wang L; Chahoud J; Chakrabarti R; Yeo CD; Luu HN; Pietro GD; Parker A; Park JY
Cancer Med; 2020 Nov; 9(22):8662-8675. PubMed ID: 32986937
[TBL] [Abstract][Full Text] [Related]
37. Exploration of immune-related genes in high and low tumor mutation burden groups of chromophobe renal cell carcinoma.
Li L; Chen X; Hao L; Chen Q; Liu H; Zhou Q
Biosci Rep; 2020 Jul; 40(7):. PubMed ID: 32662515
[TBL] [Abstract][Full Text] [Related]
38. Higher programmed cell death 1 ligand 1 (PD-L1) mRNA level in clear cell renal cell carcinomas is associated with a favorable outcome due to the active immune responses in tumor tissues.
Ning XH; Gong YQ; He SM; Li T; Wang JY; Peng SH; Chen JC; Liu JY; Qi NN; Guo YL; Gong K
Oncotarget; 2017 Jan; 8(2):3355-3363. PubMed ID: 27926518
[TBL] [Abstract][Full Text] [Related]
39. Construction of immune-related risk signature for renal papillary cell carcinoma.
Wang Z; Song Q; Yang Z; Chen J; Shang J; Ju W
Cancer Med; 2019 Jan; 8(1):289-304. PubMed ID: 30516029
[TBL] [Abstract][Full Text] [Related]
40. HJURP is a prognostic biomarker for clear cell renal cell carcinoma and is linked to immune infiltration.
Zhang F; Yuan D; Song J; Chen W; Wang W; Zhu G; Hu B; Chen X; Zhu J
Int Immunopharmacol; 2021 Oct; 99():107899. PubMed ID: 34217993
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
